Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM)
06 October 2009 - 11:00PM
PR Newswire (US)
To Launch MuGard Through iMedicor's Proprietary Alerts System
Application DALLAS, Oct. 6 /PRNewswire-FirstCall/ -- ACCESS
PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today
that it had signed an agreement with iMedicor (OTC:VMCI) (BULLETIN
BOARD: VMCI) for the North American commercial launch of MuGard,
its FDA approved mucoadhesive oral rinse for the management of oral
mucositis and stomatitis caused by radiotherapy and/or
chemotherapy. Using iMedicor's highly targeted Alerts System
application, initial introduction of MuGard to the 216,000 selected
physicians in the US is expected to begin by the end of the year.
MuGard is being commercially launched worldwide, with initial
launches in the United Kingdom, Germany, Italy, Norway and Greece
having been previously announced. Access expects additional
commercial launches in Europe, and in the Far East through two
partners to start shortly. "We look forward to working with Access
Pharma to help them introduce MuGard in a cost effective,
non-intrusive manner, a potential blockbuster product which could
significantly improve the quality of life for patients undergoing
certain cancer treatments," said Fred Zolla, CEO of Vemics
iMedicor. "Using our Alert System, iMedicor's ability to deliver
essential information from a trusted source to specific physician
audiences will significantly increase our client's marketing ROI."
MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for
the management of oral mucositis, a debilitating side effect of
many anticancer treatments. Up to 80% of all patients receiving
radiotherapy and approximately 40% of all chemotherapy patients
develop oral mucositis, and almost all patients receiving
radiotherapy for head and neck cancer and those undergoing stem
cell transplantation develop mucositis. Updated clinical practice
guidelines for the prevention and treatment of mucositis recommend
the use of a preventive oral care regimen as part of routine
supportive care along with a therapeutic oral care regimen if
mucositis develops. The market for the treatment of oral mucositis,
expanding to include all patients undergoing chemotherapy and
radiotherapy, is estimated to be in excess of $5 billion
world-wide. "We are excited about iMedicor's ability to introduce
MuGard more rapidly and to a broad physician audience than we would
expect through traditional distribution channels," said Access' CEO
Jeffrey Davis. "We believe through this new marketing partnership
with iMedicor, Access will be able to reach a broad spectrum of
oncologists, radiation oncologists and other key clinicians in a
very cost-effective manner, to utilize the medical education
aspects of the system to educate about oral mucositis and MuGard,
and to accelerate commercial uptake in the US market." About
iMedicor: iMedicor is the only HIPAA-compliant solution for
interoperable health information transfer that is offered to
physicians, healthcare providers and patients at no cost. The
iMedicor portal enables disparate EMR (electronic medical record)
systems to communicate, collaborate and exchange records in real
time; pharmaceutical companies to deliver customized educational
marketing programs to more than 730,000 healthcare providers
nationwide in a highly targeted, cost-effective and non-intrusive
manner. More information on iMedicor is available at
http://www.imedicor.com/. About Access: Access Pharmaceuticals,
Inc. is an emerging biopharmaceutical company that develops and
commercializes propriety products for the treatment and supportive
care of cancer patients. Access' products include ProLindac(TM),
currently in Phase 2 clinical testing of patients with ovarian
cancer, and MuGard(TM) for the management of patients with
mucositis. The company also has other advanced drug delivery
technologies including Cobalamin(TM)-mediated targeted delivery and
oral drug delivery, its proprietary nanopolymer delivery technology
based on the natural vitamin B12 uptake mechanism; Angiolix®, a
humanized monoclonal antibody which acts as an anti-angiogenesis
factor and is targeted to breast cancer; and Thiarabine, a new
generation nucleoside analog which has demonstrated both
pre-clinical and clinical activity in certain cancers. For
additional information on Access Pharmaceuticals, please visit our
website at http://www.accesspharma.com/. This press release
contains certain statements that are forward-looking within the
meaning of Section 27a of the Securities Act of 1933, as amended,
and that involve risks and uncertainties. These statements include
those relating to: clinical trial plans and timelines and clinical
results for ProLindac and product candidates acquired in the
MacroChem transaction, our ability to execute licensing agreements
in the future, Access' plans to continue and initiate clinical
trials, the value of its products in the market (including MuGard
and the size of the overall market for mucositis products), its
ability to achieve clinical and commercial success and its ability
to successfully develop marketed products. These statements are
subject to numerous risks, including but not limited Access' need
to obtain additional financing in order to continue the clinical
trial and operations and to the risks detailed in Access' Annual
Reports on Form 10-K and other reports filed by Access with the
Securities and Exchange Commission. Contact: Company Contact:
Investor Relations Stephen B. Thompson Donald C. Weinberger/Diana
Bittner (media) Vice President, Wolfe Axelrod Weinberger Assoc. LLC
Chief Financial Officer (212) 370-4500 Access Pharmaceuticals, Inc.
(214) 905-5100 DATASOURCE: Access Pharmaceuticals, Inc. CONTACT:
Stephen B. Thompson, Vice President, Chief Financial Officer of
Access Pharmaceuticals, Inc., +1-214-905-5100; or Investor
Relations, Donald C. Weinberger or Diana Bittner (media) of Wolfe
Axelrod Weinberger Assoc. LLC, +1-212-370-4500, for Access
Pharmaceuticals, Inc. Web Site: http://www.accesspharma.com/
http://www.imedicor.com/
Copyright